tbuckley/cabot-search huggingface dataset:
792P Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
Authors: P. Corbaux, B. You, R.M. Glasspool, N. Yanaihara, A. Tinker, K. Lindemann, M.R. Mirza, I. Ray-Coquard, F. Subtil, O. Colomban, J. Peron, E. Karamouza, I. McNeish, C. Kelly, T. Kagimura, S. Welch, L-A. Lewsley, X. Paoletti, A. Cook
Journal: Annals of Oncology (2023)
1532P Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Authors: S. Yamamoto, K. Muro, K. Nishino, H. Kawakami, T. Kojima, H. Ojima, Y. Tanaka, K. Suyama, N. Machida, K. Koyanagi, K. Iijima, H. Hirai, M. Chisamore, K. Chin
Journal: Annals of Oncology (2023)
861P Combined patient specific tumor and HPV sequencing enables high sensitivity detection of ctDNA in HPV-associated oropharyngeal carcinoma patients
Authors: B.H. Diplas, D. Brown, X. Pei, C. Graybill, A. Novaj, W.M. Korn, R. Daber, J. Humm, A. Shukla-Dave, H. Schoder, N. Katabi, L. Chen, E.J. Sherman, N. Lee, N. Riaz, J.S. Reis-Filho
Journal: Annals of Oncology (2023)
93P Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
Authors: T.S. Gerashchenko, A. Frolova, A.A. Fedorov, M. Patysheva, M. Vashisth, P. Iamshchikov, O. Bragina, N. Cherdyntseva
Journal: Annals of Oncology (2023)
1590P Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Authors: B. Freile, S. Derks, T. van Schooten, F. Carneiro, R. Barros, C. Caballero, C.V. Gauna Colas, A. Riquelme, G. Pizarro, M. Garrido, E. Ruiz, E. Fernandez-Figueroa, A.M. Leon Takahashi, J. Mariani, M.R. Luca, J.M.R. O'Connor, F. Esteso, A. Cervantes, T.C. Fleitas
Journal: Annals of Oncology (2023)
862P Clinical utility of circulating tumor HPV16 DNA detection in plasma from oropharyngeal squamous cell carcinoma patients
Authors: A.C. de Carvalho, L. Torrens, P. Chopard, V. Gaborieau, R. Cortez, T. Waterboer, P. Saintigny, P-E. Roux, S. Virani, P. Brennan, S. Perdomo
Journal: Annals of Oncology (2023)
606P Regional lymph nodes (N+ vs N0) in metastatic colorectal cancer
Authors: E. Osterlund, H. Isoniemi, H. Sorbye, P. Pfeiffer, L. Nunes, P. Halonen, A. Uutela, T. Salminen, A. Algars, R. Ristamaki, R. Kallio, A. Lamminmäki, A. Ristimäki, L. Nieminen, J. Sundström, M.J. Mäkinen, S. Kytölä, T. Sjöblom, B. Glimelius, P.J. Osterlund
Journal: Annals of Oncology (2023)
872P Prognostic value of pathological intratumor heterogeneity in patients with head and neck squamous cell carcinoma treated with upfront surgery
Authors: C. Lamy, G. Marret, H. Diallo, D. Berger, A. Kadi, A-S. Plissonnier, S. Vacher, Z. El Beaino, J. Klijanienko, C. Martinat, E. Jeannot, J. Martin, N. Badois, M. Lesnik, A. Dubray Vautrin, O. Choussy, R. Taouachi, I. Bieche, M. Kamal, C. Le Tourneau
Journal: Annals of Oncology (2023)
63P Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Authors: A.C. Cismaru, C. Tomuleasa, S. Chira, E. Isacescu, G. Cismaru, L-M. Gherman, D.T. Gulei, R. Muntean, I. Berindan-Neagoe
Journal: Annals of Oncology (2023)
1575P Factors associated with uptake of adjuvant nivolumab in a nationwide esophageal cancer patient cohort
Authors: R.H.A. Verhoeven, N. Haj Mohammad, P. Vissers, D. Bertwistle, P. Singh, M. van Berge Henegouwen, R. Van Hillegersberg, P. Jeene, L. Kodach, S.M. Lagarde, M. Luyer, B. Mostert, J. van Sandick, M. Visser, M. Slingerland, B.P.L. Wijnhoven, H.W.M. van Laarhoven
Journal: Annals of Oncology (2023)
853O OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase II trial
Authors: J. Thariat, M. Bosset, A. Falcoz, D. Vernerey, Y. Pointreau, S. Racadot, J.C. Faivre, J. Castelli, S. Guihard, F. Huguet, S. Chapet, Y. Tao, J. Bourhis, X.S. Sun
Journal: Annals of Oncology (2023)
1558P Preoperative pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma (ESCC): The phase II Keystone-001 trial
Authors: H. Jiang, X. Shang, Y. Xie, G. Zhao, C. Zhang, W. Zhang, L. Liu, R. Li, J. Yue, C. Chen, X. Duan, Z. Ma, Y. Sun, J. Yu, X. Ren
Journal: Annals of Oncology (2023)
614P Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Authors: J. Tabernero, G. Prager, M. Fakih, F. Ciardiello, E. Van Cutsem, M.E. Elez Fernandez, F.J.S.M. Cruz, L.S. Wyrwicz, D. Stroyakovskiy, Z. Pápai, E. Martinelli, L. Salvatore, P.G. Poureau, G. Liposits, C. Cremolini, D.P. Modest, N. Causse-Amellal, L. Roby, D. Skanji, J. Taieb
Journal: Annals of Oncology (2023)
1584P Conversion effect of PD-1 antibody camrelizumab (Cam) combined with modified FLOT (mFLOT) regimen in patients(pts) with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Authors: Q. Geng, W. Feng, H. Huang, X. Zhao, H. Fu, Y. Zhou, W. Zhang, M. Huang, G. Zhao, D. Xu, W. Guo
Journal: Annals of Oncology (2023)
1526P Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Authors: Z.A. Wainberg, K. Yamaguchi, J.A. Ajani, J. Chao, M. Moehler, Y-K. Kang, E. Van Cutsem, P. Yen, Y. Motii, D. Zhou, T. Murias Dos Santos, K. Shitara
Journal: Annals of Oncology (2023)
1514P Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update
Authors: R. Hubner, J. Xu, K. Kato, E. Raymond, Y. Shu, Y. Pan, Y. Jiang, J. Zhang, S.R. Park, T. Kojima, C-Y. Lin, E. Gotovkin, L.S. Wyrwicz, R. Ishihara, H. Wu, Y. Peng, L. Wang, L. Li, H.H. Yoon
Journal: Annals of Oncology (2023)
604P Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO)
Authors: M. Koopman, R. Garcia-Carbonero, C. Pinto, A. Mitroshkin, G. Bodoky, L. Mineur, V. Bourgeois, M. Mare, A. Ruiz-Casado, A. Fernandez Montes, J.M.R. O'Connor, A. Sullivan, E. Choucair, M. Sicaire, F.E. Marti, J-B. Bachet
Journal: Annals of Oncology (2023)
1516P Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Authors: M. Lowery, L. Wyrwicz, D-Y. Oh, K-K. Shiu, P. Yanez Weber, Y. Bai, J. Lee, F. Rivera, G. Alves, M. Garrido, M. González Fernández, J. Li, T. Cil, F. Cruz, S. Qin, L. Yin, A. Valderrama, S. Bordia, S.Y. Rha
Journal: Annals of Oncology (2023)
1591P Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Authors: T. Esakia, E. Smyth, M. Abuladze, E. Mariamidze, N. Sharikadze, M. Maglakelidze, K. Tsiklauri, T. Rukhadze
Journal: Annals of Oncology (2023)
786P Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Authors: K. Hasegawa, S. Yagishita, D. Shintani, H. Yoshida, M. Suzuki, S. Sato, A. Ogasawara, T. Nishikawa, K. Yonemori, M. Yasuda, K. Furuuchi, T. Uenaka, A. Hamada
Journal: Annals of Oncology (2023)
80P Steroidal oximes: A new potential therapeutic approach for cancer treatment
Authors: M. Laranjo, A.R. Gomes, S. Costa, A.M. Abrantes, A.C. Gonçalves, R. Alves, M.F. Botelho, E. Tavares-da-Silva, S. Pires, F. Roleira
Journal: Annals of Oncology (2023)
626P Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
Authors: F.J. Ros Montana, V. Navarro, R. Comas, S. Landolfi, L. Ramirez, H.G. Palmer, A. Garcia Rodriguez, N. Saoudi Gonzalez, I. Baraibar Argota, M. Rodriguez Castells, F. Salvà Ballabrera, J. Tabernero, M.E. Elez Fernandez
Journal: Annals of Oncology (2023)
779P Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Authors: C. Garcia Duran, H. Domenech, G. Villacampa Javierre, L. Fariñas Madrid, S. Simonetti, D.G. Illescas, V. Serra Elizalde, J.F. Grau Béjar, R. Mazzeo, A. Llop-Guevara, A. Oaknin
Journal: Annals of Oncology (2023)
610P Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
Authors: M.J.G. Bond, M. van Smeden, K. Degeling, C. Cremolini, H.J.E-V. Schmoll, D. Rossini, S. Ibach, M. Koopman, C.J.A. Punt, A.M. May, J.J. Kwakman
Journal: Annals of Oncology (2023)
56P SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Authors: C. Dijkhuizen, P. Korthuis, J. Vilacha, M. Smelt, A.J. Van Der Wekken, A. van den Berg, L. Drayer
Journal: Annals of Oncology (2023)
1520P Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
Authors: M. Dos Santos, J. Lequesne, G. Piessen, R. Desgrippes, R. Guimbaud, S. Pernot, O. Bouche, S. Hiret, E. Soularue, L. Dahan, D. Tougeron, C. Borg, S.M. Le Sourd, E. Samalin-Scalzi, M. Tellier-Castera, A. Leconte, B. Clarisse
Journal: Annals of Oncology (2023)
1548P PD-L1 assessment in oesophageal and gastro-oesophageal adenocarcinoma with PD-L1 IHC 22C3 pharmDx and PD-L1 IHC 28-8 pharmDx assays on Autostainer Link 48: The University Hospitals Birmingham experience over a period of 18 months
Authors: B. O'Sullivan, P. Taniere, K. Charles, J. Pritchard, S. Gawthorpe, J. Thompson, J. Dowds, S. Diaz-Cano
Journal: Annals of Oncology (2023)
918P SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Authors: L. Ying, H. Zongwei, C. Xiaochuan, S. Qiu
Journal: Annals of Oncology (2023)

The M2 macrophages in the tumor immune microenvironment (TIME) have been identified as independent prognostic factors in nasopharyngeal carcinoma (NPC). However, the clinical significance of SPP1-related M2 macrophages remains largely unexplored. To reconstruct a pseudotime trajectory of macrophage polarization in NPC and analyze the gene expression patterns along the trajectory, we applied publicly available single-cell sequencing data (GSE150825). GeneSwitches was used to sequence the critical regulatory genes during M2 macrophage activation and identify their order. To construct the M2 macrophage-activation genes signature (MAGens), we analyzed the transcriptome data of the Fujian NPC dataset (N=188) and the published dataset (GSE102349, N=88) using 101 combinations of machine learning algorithms that included univariate and correlation analyses. We utilized single-cell transcriptomics and GeneSwitches analyses to identify SPP1 as the top switching gene in M2 macrophage activation and determine the order of the switch. Analysis of the bulk transcriptome revealed that high expression of SPP1 is associated with poor prognosis and increased infiltration of M2 macrophages, which was validated using immunohistochemistry. We then established a 13-gene MAGens that accurately predicts progression-free survival in patients with nasopharyngeal carcinoma (NPC) (5-year AUC: 0.95) and serves as an independent prognostic factor based on uni- and multivariate analyses. We found that the low MAGens group had a higher level of immune infiltrating cells and immune modulators, indicating an inflamed but relatively immunosuppressive microenvironment that could potentially benefit from immunotherapy. Lastly, we verified the predictive value of MAGens in the Fujian NPC dataset, where MAGens score exhibited a significant positive correlation with known immunotherapy indicators CD8, PD-1, and PD-L1. As a new predictive biomarker, MAGens offer significantly improved precision in selecting the NPC population that could benefit from immunotherapy. We recommend the immediate validation and application of these unique MAGens.
1586P Characteristics, treatment (Tx) patterns and outcomes of patients with advanced/metastatic gastric cancer (GC) or gastro-esophageal junction (GEJ) adenocarcinoma previously treated with anti-HER2 therapy in an English national registry
Authors: N. Starling, L. Zhang, K. Dunton, A. Struebing, Y. Xiong, C. Livings, L. Brannman, M. Yakhchi Beykloo, H. Mohamed, N. Trankov, P. Egger
Journal: Annals of Oncology (2023)
1563P Tumor-intrinsic subtypes of esophageal adenocarcinoma associate cellular phenotypes with responses to therapy
Authors: D. Blangé, M. Dings, A. van der Zalm, M. Lansbergen, M. Verzaal, C. Oyarce, S. Meijer, C. Waasdorp, M. van Mourik, C. Longobardi, E. Cuppen, H. Bloemendal, J. Koster, D. Zwijnenbrug, J-P. Medema, H.W.M. van Laarhoven, M.F. Bijlsma
Journal: Annals of Oncology (2023)
776P Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Authors: D. Afenteva, T.A. Muranen, A. Rajavuori, S. Jamalzadeh, K. Zhang, V. Ariotta, V-M. Isoviita, A. Lahtinen, K.A. Lavikka, O. Lehtonen, Y. Li, G. Marchi, J. Oikkonen, S. Salloum, K. Huhtinen, S. Hietanen, A. Virtanen, J. Hynninen, S. Hautaniemi
Journal: Annals of Oncology (2023)
867P Predicting HPV-association using regular H&amp;E slides can identify subgroups of patients with favorable prognosis at a highly detailed level
Authors: J.P.P. Klussmann, N. Würdemann, I. Demers, S. Wagner, C. Kopp, A. Charpentier, S.J. Sharma, J. George, J. Hess, R. Büttner, E-J. Speel, H.C. Reinhardt, S. Klein
Journal: Annals of Oncology (2023)
612P Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Authors: F. Zhou, W. Wang, L. Xia, J. Dai, H. Wu, L. Yang, J. Gong, X. Chen, Z. Xiong, X. Liang
Journal: Annals of Oncology (2023)
1534P First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 study
Authors: J-M. Sun, C-Y. Lin, C. Rojas, F. Rivera, D. Kwong, M-H. Chen, Y. Zhang, S. Yamamoto, L. Yu, S. Shah, P. Bhagia, L. Shen
Journal: Annals of Oncology (2023)
1565P ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Authors: G.A. Keogh, D. Chai Kai Ann, D. Cunningham, R.E. Langley, W. Allum, M. Nankivell, P. Tan, R. Sundar, H.I. Grabsch
Journal: Annals of Oncology (2023)
359P Unveiling the factors influencing exercise engagement in breast cancer patients: Insights from the early recovery phase
Authors: S. Yeon, J. Min, J.Y. Kim, S.I. Kim, T.H. Lee, D-H. Park, R. Park, J.W. Kang, Y.J. Lee, C. Oh, E. Kim, S. Jun, K. Chiho, J. Jeon
Journal: Annals of Oncology (2023)
607P Impact of primary tumour sidedness (PTS) on demographics, resectability, and outcome after metastasectomy +/- local ablative therapy (LAT), or systemic therapy in metastatic colorectal cancer patients (a RAXO substudy)
Authors: P.J. Osterlund, E. Osterlund, P. Halonen, L-M. Soveri, A. Nordin, A. Uutela, T. Salminen, K.I. Lehtomaki, S. Aho, A. Algars, R. Ristamaki, E. Heerva, R. Kallio, A. Lamminmäki, H.P. Stedt, T.T. Muhonen, T. Kuopio, J.T. Kononen, B. Glimelius, H. Isoniemi
Journal: Annals of Oncology (2023)
1527P Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Authors: J. Yuan, L. Shen, T. Liu, H. Xu, J. Yang, J. Wei, H. Jiang, Y. Deng, Y. Wang, X. Zhang, J. Gong, C. Lyu, Y. Li, L. Song
Journal: Annals of Oncology (2023)
617P Predictive and prognostic impact of primary tumor location on sequential treatment with regorafenib and trifluridine/tipiracil at third line and beyond in metastatic colorectal cancer: A real-world multicenter retrospective analysis
Authors: C. Signorelli, M.A. Calegari, M. Basso, A. Anghelone, J. Lucchetti, A. Minelli, L. Angotti, I.V. Zurlo, M. Schirripa, M.G. Chilelli, C. Morelli, E. Dell'Aquila, D. Gemma, M. Ribelli, G. Arrivi, F. Zoratto, M.G. Morandi, F. Santamaria, R. Saltarelli, E.M. Ruggeri
Journal: Annals of Oncology (2023)
620P A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Authors: G. Martini, T. Troiani, D. Ciardiello, S. Napolitano, V. Famiglietti, G. Arrichiello, L. Esposito, R. Franco, F. Zito Marino, I. Panarese, C. Cardone, E. Maiello, T.P. Latiano, A. Avallone, P.P. Vitiello, E. Mariella, A. Reginelli, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2023)
1542P Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
Authors: M. Xu, Y. Pu, Y. Jiang, H. Liu, Y. Feng, C. Qian, N. Dai, M. Li
Journal: Annals of Oncology (2023)
794P Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
Authors: J. Loh, N.Y.L. Ngoi, F. Blanc-Durand, S.Y.R. Ang, E. Elias, A. Lai, D. Lim, Y.W. Lim, S.E. Lim, J. Low, J. Ng, V. Sundararajan, Y.L. Thian, P. Tong, S. Wijaya, D.S. Tan
Journal: Annals of Oncology (2023)
855MO Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)
Authors: J. Guerlain, N. Cozic, A. Daste, O. Malard, J. Fayette, F. Rolland, O. Mauvais, A.C. Johnson, S. Salas, M. Vinches, A. Bozec, S. Vergez, E. de Monès, I. Breuskin, M. Iacob, B. Archambaud, F. Janot, C. Even
Journal: Annals of Oncology (2023)
1398P Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Authors: S.M. Ernst, P. de Bruijn, T.E. van der Horst, M.S. Paats, J.G. Aerts, R.H. Mathijssen, S.L. Koolen, A-M.C. Dingemans
Journal: Annals of Oncology (2023)
59P Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Authors: C. Ngamchokwathana, S. Santisukwongchote, N. Zungsontiporn, P. Sitthideatphaiboon, P. Chantranuwat, C. Vinayanuwattikun
Journal: Annals of Oncology (2023)
1391P Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Authors: O.J. Juan Vidal, M.K. Singhal, R.M. Alvarez, F.L. Cecere, P-J. Souquet, S-W. Kim, A. Robeva, A. Jary, S. Glaser, M. Miskic, J. Wolf
Journal: Annals of Oncology (2023)
1220P Comprehensive diagnose of programmed death-ligand 1 from two-dimensional to three-dimensional in breast cancer with computer-aided artificial intelligence system
Authors: Y-H. Lee, Y-C. Lin, Y-H. Hsieh, C-H. Yang, Y-A. Chen, C-H. Lin, M-Y. Wang, W-H. Kuo, Y-Y. Lin, Y-S. Lu
Journal: Annals of Oncology (2023)
1334P Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Authors: A.M. Grecea, M.R. Ghigna, A. Marinello, J. Remon Masip, D. Vasseur, M-L. Meyer, D. Soldato, P. Lavaud, A. Gazzah, P. Abdayem, M. Frelaut, I. Kasraoui, C.A. Garcia, A. Botticella, A. Levy, J-Y. Scoazec, F. Barlesi, D. Planchard, B. Besse, M. Aldea
Journal: Annals of Oncology (2023)

SMARCA4 deficient (SMARCA4d) non-small cell lung cancer (NSCLC) has a poor prognosis. The activity of first line immune-checkpoint blockers (ICB) or chemo-ICB and the potential impact of co-mutations is scarcely explored in patients with SMARCA4d NSCLC. This is a monocentric, retrospective study evaluating patients with advanced NSCLC, screened for SMARCA4 alterations and treated with first line chemo-ICB or ICB alone. SMARCA4d was defined as loss of BRG1 in immunohistochemistry or the presence of deleterious SMARCA4 in liquid or tissue biopsies assessed by next-generation sequencing. Progression-free survival (PFS), overall survival (OS) and the impact of co-mutations (STK11, KEAP1) were compared between patients with or without SMARCA4d. A total of 128 patients were included: 36 with SMARCA4d (12 in IHC, 31 in NGS, 7 both) and 92 without SMARCA4d (control group). Patients with SMARCA4d had a median age of 57 years, were male in 64% cases and smokers in 94% cases, similar to the control group. Histology type was adenocarcinoma in 53% versus 82% (p<0.001) in control, with more cases of undifferentiated or large cell neuroendocrine carcinoma in the SMARCA4d group. TMB value was 13 vs 5 mut/Mb (p<0.001), median PD-L1 expression was 0 vs 5% (p=0.3) in SMARCA4d versus control, with no differences in immune blood counts. STK11 and KEAP1 mutations were frequently co-mutated with SMARCA4d (53% vs 26%, p= 0,01; 37% vs 13%, p= 0,01, respectively. The median PFS under ICB+/- chemotherapy was 4.0 months (CI 95% 2.87- 7.7) vs 7.37 months (CI 95% 6.53-11.3) (p= 0.005) in SMARCA4d versus control, and the median OS was 9.3 months (CI 95% 7.0 – NR) vs 27.6 months (CI 95% 27.3 - NA) (p< 0.0001), respectively. In patients with STK11/KEAP1 mutations, median OS was 7 months (95% CI 5-NR) versus 13.3 months (95% CI 10.5-35.8) (p=0.19) in SMARCA4 and control, respectively. SMARCA4d seems to negatively impact survival outcomes and the efficacy of ICB, despite high TMB. Novel treatments are rapidly needed.
611P SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study
Authors: R-H. Xu, M. Qiu, Y. Bai, J. Wang, K. Gu, M. Yang, Y. He, C. Yi, Y. Jin, B. Liu, F. Wang, C. Huang, Y. Jiang
Journal: Annals of Oncology (2023)
1326P Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
Authors: D. Planchard, A.C. Toffart, A-C. Madroszyk Flandin, M. Wislez, S. Martinez, I. Monnet, S. Hiret, V. Gounant, A-C. Métivier, C. Domblides, E. Giroux-Leprieur, E. Huchot, P. Tomasini, C. Mascaux, D. Carmier, A. Langlais, F. Morin, V. Westeel, A. Cortot
Journal: Annals of Oncology (2023)
803P Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Authors: S. Nishio, K. Murotani, W. Yamagami, S. Suzuki, H. Nakai, K. Kato, H. Tokunaga, H. Nomura, Y. Yokoyama, K. Takehara
Journal: Annals of Oncology (2023)
1389P Efficacy of poziotinib in HER2 exon 20 insertion NSCLC patients who received prior platinum-based and HER2 targeted therapies
Authors: A. Prelaj, X. Le, C. Proto, C.S. Baik, N. Tchekmedyian, J. Heymach, G. Bhat, R. Cornelissen
Journal: Annals of Oncology (2023)
1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Authors: A. Schram, K. Goto, D-W. Kim, A. Hollebecque, S.Y. Rha, K. Nishino, M. Duruisseaux, K. Umemoto, J.O. Park, N. Leighl, T. Macarulla, S.V. Liu, M.N. Al-Hallak, J. Cleary, C. Neuzillet, Y. Goto, A.K. Joe, S. Adeyemi, S. Jauhari, A. Drilon
Journal: Annals of Oncology (2023)
811P Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Authors: G. Zibetti Dal Molin, A. dos Santos, M. Olivera, R. Ribeiro, J.J. Zarba, A.P. Guerrero, A.M. Reyes Morales, A.C. de Melo, G. Werutsky, H. de Andrade Carvalho, E.H.C. Silva, R.L. Schmidt, M. Acevedo Zarzar de Melo, F.B. Damian, M.G. Raimondo, A. Mattar, R. de Jesus, G.C.D.L. Gossling, R. Colombo Bonadio
Journal: Annals of Oncology (2023)